.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Accenture
Federal Trade Commission
Chubb
Medtronic
Covington
Daiichi Sankyo
Mallinckrodt
Healthtrust
US Department of Justice

Generated: June 28, 2017

DrugPatentWatch Database Preview

Alendronate sodium - Generic Drug Details

« Back to Dashboard

What are the generic sources for alendronate sodium and what is the scope of alendronate sodium freedom to operate?

Alendronate sodium
is the generic ingredient in four branded drugs marketed by Impax Labs Inc, West-ward Pharms Int, Sun Pharma Global, Aurobindo Pharma, Mylan, Mission Pharma, Dr Reddys Labs Ltd, Jubilant Cadista, Austarpharma Llc, Merck And Co Inc, Cipla Ltd, Upsher-smith Labs, Merck, Apotex, Teva Pharms, and Watson Labs, and is included in eighteen NDAs. There are six patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Alendronate sodium has ninety-six patent family members in forty countries.

There are twenty-five drug master file entries for alendronate sodium. Twenty-nine suppliers are listed for this compound.

Summary for Generic Name: alendronate sodium

Tradenames:4
Patents:6
Applicants:16
NDAs:18
Drug Master File Entries: see list25
Suppliers / Packagers: see list29
Bulk Api Vendors: see list127
Clinical Trials: see list2,464
Patent Applications: see list7,614
Therapeutic Class:Metabolic Bone Disease Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:alendronate sodium at DailyMed

Pharmacology for Ingredient: alendronate sodium

Ingredient-typeDiphosphonates
Drug ClassBisphosphonate
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cipla Ltd
ALENDRONATE SODIUM
alendronate sodium
TABLET;ORAL076768-001Aug 4, 2008ABRXNoNo► Subscribe► Subscribe
Jubilant Cadista
ALENDRONATE SODIUM
alendronate sodium
TABLET;ORAL090557-002Feb 18, 2010ABRXNoNo► Subscribe► Subscribe
Upsher-smith Labs
ALENDRONATE SODIUM
alendronate sodium
TABLET;ORAL075871-005Apr 22, 2009DISCNNoNo► Subscribe► Subscribe
Jubilant Cadista
ALENDRONATE SODIUM
alendronate sodium
TABLET;ORAL090557-004Feb 18, 2010ABRXNoNo► Subscribe► Subscribe
Cipla Ltd
ALENDRONATE SODIUM
alendronate sodium
TABLET;ORAL076768-005Aug 4, 2008ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: alendronate sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-001Sep 29, 19956,090,410*PED► Subscribe
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-001Sep 29, 19956,194,004*PED► Subscribe
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-002Sep 29, 19955,358,941*PED► Subscribe
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-003Apr 25, 19975,804,570► Subscribe
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-001Sep 29, 19955,804,570► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: alendronate sodium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,432,932 Method for inhibiting bone resorption► Subscribe
6,544,967 Method for inhibiting bone resorption► Subscribe
8,449,906Effervescent compositions comprising phosphonates and methods related thereto► Subscribe
6,333,316 Method for inhibiting bone resorption► Subscribe
6,465,443 Method for inhibiting bone resorption► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: alendronate sodium

Country Document Number Estimated Expiration
Malaysia118194► Subscribe
Austria541575► Subscribe
Denmark1175904► Subscribe
China1602879► Subscribe
Singapore139556► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ALENDRONATE SODIUM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1175904/01Switzerland► SubscribeFORMER OWNER: SCHERING CORPORATION, US
222Luxembourg► Subscribe91222, EXPIRES: 20200824
2006002,C0998292Lithuania► SubscribePRODUCT NAME: NATRIUM ALENDRONICUM/COLECACIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001, EU/1/05/310/002, EU/1/05/310/003, EU/1/05/310/004, EU/1/05/310/005 20050824
2006002Lithuania► SubscribePRODUCT NAME: NATRIUM ALENDRONICUM/COLECACIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001, EU/1/05/310/002, EU/1/05/310/003, EU/1/05/310/004, EU/1/05/310/005 20050824
364Luxembourg► Subscribe91364, EXPIRES: 20200826
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Mallinckrodt
Queensland Health
Cantor Fitzgerald
Dow
US Army
UBS
QuintilesIMS
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot